Novo Nordisk and Heartseed have entered an exclusive global partnership and license agreement over the development, production and marketing of Heartseed's HS-001 to treat cardiovascular diseases, Novo Nordisk reports in a press release.
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Nordic Medical Affairs Manager 
Director for innovative pre-clinical testing unit 
Client Talent Acquisition Specialist 
Consultant Manager 
IRT Manager, Clinical Drug Supply 
(Senior) Drug Substance Specialist 
Biomarker Operations Lead 
Clinical Project Manager 
Innovation Project Manager, Display Unit 
Director of Toxicology 
Production Director 
Key Account Manager, Europe and Asia 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Account Manager 
Senior Chemical Safety Advisor 
Communications Consultant 
Laboratory technician for process development and clinical manufacturing